A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
NCT07628049
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Respiratory Syncytial Virus Infections+Metapneumovirus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- GSK Investigational Site · Stockbridge, GA
Kansas · 1
- GSK Investigational Site · Lenexa, KS
Washington · 1
- GSK Investigational Site · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.